Antiviral activity of β-L-2′,3′-dideoxy-2′,3′-didehydro-5- fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 4, 2001, Pages 1065-1077

  Le Guerhier, F ^a   Pichoud, C ^a   Jamard, C ^a   Guerret, S ^a   Chevallier, M ^a   Peyrol, S ^a   Hantz, O ^a   King, I ^a   Trepo C ^a   Cheng, Y C ^a   Zoulim, F ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 2,3 DIDEHYDRO 5 FLUOROCYTIDINE; CIRCULAR DNA; CYTIDINE DERIVATIVE; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; BILE DUCT; CLINICAL PROTOCOL; DNA SYNTHESIS; DRUG INHIBITION; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; HEPATIC DUCT; HEPATITIS; HEPATITIS B VIRUS; LIVER CELL; LIVER CELL CARCINOMA; LIVER MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; SKIN PIGMENTATION; VIREMIA; VIRUS REPLICATION; WEIGHT REDUCTION; WOODCHUCK;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, CIRCULAR; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; LAMIVUDINE; LIVER; MARMOTA; SKIN PIGMENTATION; VIREMIA; VIRUS REPLICATION; ZALCITABINE;

EID: 0035084728     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.4.1065-1077.2001     Document Type: Article

References (49)

1. Enzyme-altered liver cell foci in woodchucks infected with woodchuck hepatitis virus
2. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
3. An algorithm for the grading of activity in chronic hepatitis C
4. Synthesis and comparative evaluation of two antiviral agents: Beta-L-Fd4C and beta-D-Fd4C
5. Antigenic analysis of woodchuck hepatitis virus surface antigen with site-specific radioimmunoassays
6. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine cytosine in woodchuck hepatitis virus-infected woodchucks
7. Lamivudine as initial treatment for chronic hepatitis B in the United States
8. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumors
9. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks
10. The carbocyclic analog of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver
11. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: Comparison with the hepatitis B virus sequence
12. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
13. Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma
14. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy
15. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections
16. Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases
17. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B
18. Pharmacodynamics of (-)-β-2′,3′-dideoxy-3′-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans
19. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
20. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement
21. Woodchuck hepatitis virus infections: Very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte
22. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: Evolutional relationship between hepadnaviruses
23. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks
24. A one year trial of lamivudine for chronic hepatitis B
25. Hepatitis B virus infection
26. Characterization of the antiviral effect of 2′, 3′-dideoxy-2′, 3′-didehydro-β-L-5-fluorocytidine in the duck hepatitis B virus infection model
27. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo
28. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5- fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human immuno-deficiency virus (HIV) in vitro
29. Lamivudine therapy of WHV-infected woodchucks
30. Experimental systems for the study of hepadnavirus and hepatitis delta virus infections
31. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
32. Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks
33. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl) adenine, an acyclic phosphonate nucleoside analogue
34. Viral dynamics in hepatitis B virus infection
35. Selective cutaneous hyperpigmentation in mice following zidovudine administration
36. Hepatocarcinogenicity of the woodchuck hepatitis virus
37. Pharmacokinetics of (-)-2′,3′-dideoxy-3′-thiacytidine in woodchucks
38. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein
39. Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (D4FC) analogues: Discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase
40. Three recently described animal virus models for human hepatitis B virus
41. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks
42. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepattis B virus infection
43. Quantitative studies on liver fibrosis and alpha-smooth muscle actin expression in heroin abusers
44. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
45. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′didehydro-β-L-(-)-5- fluorocytidine
46. Therapy of chronic hepatitis B virus infection: Inhibition of the viral polymerase and other antiviral strategies
47. 2′,3′-Dideoxy-β-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo
48. Woodchuck hepatitis virus X protein is required for viral replication in vivo
49. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy